Dergiler / Turkish Journal of Hematology / 2021 / Cilt: 38 - Sayı: 2

Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study

HLA-Uyumlu Allojenik Hematopoetik Kök Hücre Akraba Nakillerinde Risk Skor Sistemlerinin Kıyaslanması: Retrospektif Kohort Çalışması

Sayfa
138–144
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: In the present study at our bone marrow and stem cell transplant center, it has been demonstrated that the HCT-CI, HCT-CI- Age, and AL-EBMT are good predictors of 2-year NRM and OS.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Allogeneic hematopoietic stem cell transplantation (AHSCT) is a potentially curative treatment of choice for many hematological diseases.
📊
Temel Bulgular & Veri:The aim of the present study was to compare 6 different risk models that are clinically used.
💡
Sonuç & Katkı:Conclusion: In the present study at our bone marrow and stem cell transplant center, it has been demonstrated that the HCT-CI, HCT-CI- Age, and AL-EBMT are good predictors of 2-year NRM and OS.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Allogeneic hematopoietic stem cell transplantation (AHSCT) is a potentially curative treatment of choice for many hematological diseases. However, there are some transplantation-related risks. Predicting the risk-benefit ratio prior to AHSCT facilitates the choice of conditioning regimens and posttransplant follow-up. Hence, many risk models have been developed. The aim of the present study was to compare 6 different risk models that are clinically used. Materials and Methods: A total of 259 patients were enrolled in this study. The European Society for Blood and Marrow Transplantation (EBMT), Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), Age-Adjusted Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI-Age), revised Pretransplant Assessment of Mortality (rPAM), Acute Leukemia-EBMT (AL-EBMT), and Disease Risk Index (DRI) risk models were applied retrospectively. Results: The AL-EBMT, HCT-CI, and HCT-CI-Age scoring systems were found to be predictive for 2-year overall survival (OS) and 2-year non-relapse mortality (NRM) (2-year OS: AL-EBMT, reference vs. score 8.5-10, HR: 1.3, p=0.035; AL-EBMT, reference vs. score >10, HR: 3.8, p=0.001; HCT-CI: reference vs. score 1-2, HR: 1.4, p=0.018; HCT- CI: reference vs. score ≥3, HR: 2.5, p 10, HR: 3.3, p<0.001; HCT-CI: reference vs. score 1-2, HR: 1.3, p=0.028; HCT-CI: reference vs. score ≥3, HR: 2.3, p=0.011; HCT-CI-Age: reference vs. score 1-2, HR: 1.3, p=0.01; HCT-CI-Age: reference vs. score ≥3, HR: 2.4, p=0.003). In terms of the Kaplan-Meier estimates of 2-year OS and 2-year NRM, the risk scoring system with the highest predictive power was found to be AL-EBMT (2-year AUC: 0.59 and 0.60, respectively). The other scores were not found to be predictive for 2-year OS and NRM. Conclusion: In the present study at our bone marrow and stem cell transplant center, it has been demonstrated that the HCT-CI, HCT-CI- Age, and AL-EBMT are good predictors of 2-year NRM and OS.

Abstract

Amaç: Allojeneik hematopoetik kök hücre nakli (AHKHN) birçok hematolojik hastalıkta kullanılan potansiyel küratif bir tedavi seçeneğidir. Bununla birlikte nakil ilişkili bazı riskler bulunmaktadır. AHKHN öncesi risk-fayda oranının belirlenmesi, kullanılacak hazırlık rejimlerinin seçimi ve nakil sonrası hasta takibini kolaylaştırmaktadır. Bu nedenle birçok risk modeli geliştirilmiştir. Bu çalışmanın amacı, klinik kullanımı olan 6 farklı risk modelini karşılaştırılmasıdır. Gereç ve Yöntemler: Bu çalışmaya çeşitli hematolojik nedenlerle AHKHN yapılan 259 hasta alınmıştır. Avrupa Kan ve Kemik iliği Nakli Derneği (EBMT), Hematopoetik Hücre Transplantasyon Komorbidite İndeksi (HCT-CI), yaşa göre düzenlenmiş Hematopoetik Hücre Transplantasyon Komorbidite İndeksi (HCT-CI-Yaş), düzenlenmiş nakil öncesi mortalite değerlendirme skoru (rPAM), akut lösemi-EBMT skoru (AL-EBMT) ve hastalık risk indeksi (DRI) risk modelleri geriye dönük olarak uygulanmıştır. Bulgular: HCT-CI, HCT-CI-Age ve AL-EBMT risk modelleri 2 yıllık genel sağkalım (OS) ve 2 yıllık NRM için prediktif bulundu (2 yıllık OS; AL-EBMT: referans vs skor 8,5-10 HR: 1,3 p=0,035 referans vs skor >10 HR: 3,8 p=0,001, HCT-CI: referans vs score 1-2 HR: 1,4 p=0,018 referans vs skor ≥3 HR: 2,5 p 10 HR: 3,3 p<0,001 HCT-CI: referans vs skor 1-2 HR: 1,3 p=0,028 referans vs skor ≥3 HR: 2,3 p=0,011 HCT-CI-Age referance vs skor 1-2 HR: 1,3 p=0,01 referans vs skor ≥3 HR: 2,4 p=0,003). İki yıllık OS ve 2 yıllık NRM için, prediktif gücü en yüksek olan test AL-EBMT idi (sırasıyla 2 yıllık AUC; 0,59-0,60). Diğer modeller 2 yıllık OS ve NRM için prediktif değildi. Sonuç: Referans nakil merkezimizde yapılan bu çalışmada, HCT-CI, HCT-CI-Yaş ve AL-EBMT risk modellerinin 2 yıllık NRM ve OS için iyi birer belirteç olduğu gösterilmiştir.

🔖

Bu Makaleye Atıf Yap

ALADAĞ, E., DEMİROĞLU, H., BÜYÜKAŞIK, Y., GÖKER, H. (2021). Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. Turkish Journal of Hematology, Cilt: 38 - Sayı: 2, 138–144. https://ajindex.com/articles/411666

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Singh AK, McGuirk JP. Allogeneic stem cell transplantation: a historical and scientific overview. Cancer Res 2016;76:6445-6451
  2. Fein JA, Shimoni A, Labopin M, Shem-Tov N, Yerushalmi R, Magen H, Furie N, Kopel E, Danylesko I, Nagler A, Shouval R. The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation. Leukemia 2018;32:1787-1794
  3. Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood 2014;124:344-353
  4. Elsawy M, Sorror ML. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2016;51:1283- 1300
  5. Potdar R, Varadi G, Fein J, Labopin M, Nagler A, Shouval R. Prognostic scoring systems in allogeneic hematopoietic stem cell transplantation: Where do we stand? Biol Blood Marrow Transplant 2017;23:1839-1846
  6. Shouval R, Fein JA, Shouval A, Danylesko I, Shem-Tov N, Zlotnik M, Yerushalmi R, Shimoni A, Nagler A. External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation. Blood Adv 2019;3:1881-1890
  7. Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, Bhatia S, Ostronoff F, Deeg HJ, Syrjala KL, Estey E, Maloney DG, Appelbaum FR, Martin PJ, Storer BE. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol 2014;32:3249-3256
  8. Barba P, Martino R, Perez-Simon JA, Fernandez-Aviles F, Castillo N, Pinana JL, Lopez-Anglada L, Rovira M, Bosch F, Carreras E, Corral LL, Sierra J, Valcarcel D. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced- toxicity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014;20:66-72
  9. Au BK, Gooley TA, Armand P, Fang M, Madtes DK, Sorror ML, Boeckh MJ, Gibson CJ, Deeg HJ, Storb R, Appelbaum FR, Chien JW, Martin PJ. Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2015;21:848-854
  10. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, Maziarz RT, Antin JH, Soiffer RJ, Weisdorf DJ, Rizzo JD, Horowitz MM, Saber W. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Bloo